INFU
Next earnings: Aug 4, 2026 · Before open
Signal
Mixed11
Price
1
Move+1.86%Positive session
Volume
1
Volume1.2× avgNormal activity
Technical
1
RSIRSI 32Momentum negative
PRICE
Prev Close
8.61
Open
8.44
Day Range8.36 – 8.77
8.36
8.77
52W Range5.08 – 11.04
5.08
11.04
62% of range
VOLUME & SIZE
Avg Volume
141.8K
FUNDAMENTALS
P/E Ratio
23.7x
EPS (TTM)
Div Yield
No dividend
Beta
0.73
Low vol
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +4% YoY · 57% gross margin
Valuation
FAIR
P/E 24x vs ~20x sector
Health
STRONG
CR 2.1 · FCF $1.00/sh
Strong Buy
Key MetricsTTM
Market Cap$176.99M
Revenue TTM$142.40M
Net Income TTM$7.91M
Free Cash Flow$20.30M
Gross Margin56.7%
Net Margin5.6%
Operating Margin9.1%
Return on Equity14.0%
Return on Assets8.0%
Debt / Equity0.39
Current Ratio2.14
EPS TTM$0.39
Alpha SignalsFull Analysis →
What Moves This Stock

Medicare/Medicaid reimbursement rate changes for ambulatory infusion services and DME codes

Oncology treatment volumes and chemotherapy utilization trends (drives pump rental demand)

Payor contract wins or losses with major health systems and oncology networks

Pump utilization rates and average rental duration per patient episode

Macro Sensitivity
Economic Cycle

low-to-moderate - Healthcare services exhibit defensive characteristics as cancer treatment and post-surgical care are non-discretionary. However, elective procedure volumes (which drive some pump demand) can decline during recessions. Commercial insurance enrollment affects payor mix, with economic downturns shifting patients toward government programs. Overall revenue is more tied to demographic trends (aging population, cancer incidence) than GDP growth, but margin pressure can emerge from cost-cutting by hospitals during economic stress.

Interest Rates

Rising rates modestly pressure valuation multiples for low-growth healthcare services stocks, as investors rotate toward higher-yielding alternatives. The company's 0.45x debt/equity suggests manageable interest expense sensitivity. Higher rates could constrain acquisition financing for industry consolidation, potentially reducing competitive M&A activity. Conversely, rate increases have minimal direct impact on operating performance since rental contracts are not rate-indexed and customer demand is clinically driven rather than financing-dependent.

Key Risks

Medicare reimbursement cuts or policy changes to DME rental categories could compress margins or eliminate product lines, as CMS periodically reviews competitive bidding programs and payment rates

Technological shift toward integrated hospital infusion systems or disposable pump technologies could reduce demand for traditional ambulatory rental pumps, particularly if hospitals vertically integrate infusion services

Regulatory compliance burden increases (FDA device reporting, HIPAA, state licensing) disproportionately impact small-cap DME providers versus larger diversified competitors with scale advantages

Investor Profile

value - The stock trades at 1.1x P/S and 7.3x EV/EBITDA, below broader healthcare equipment averages, attracting value investors seeking turnaround potential or asset-based plays. Recent 175% EPS growth (off low base) and negative 12-month return create contrarian opportunity for investors betting on operational improvement. Low institutional ownership typical of micro-cap healthcare services. Not suitable for growth investors given 7.2% revenue growth and mature DME market dynamics. Minimal dividend yield eliminates income investor appeal.

Watch on Earnings
CMS Medicare Physician Fee Schedule updates affecting DME reimbursement rates (published annually in Q4)National cancer incidence rates and chemotherapy utilization trends from SEER databaseHealthcare employment trends (PAYEMS healthcare subsector) as proxy for hospital financial health and capital spendingCommercial health insurance enrollment data indicating payor mix shifts
Health Radar
3 strong2 watch1 concern
59/100
Liquidity
2.14Strong
Leverage
0.39Strong
Coverage
15.3xStrong
ROE
14.0%Watch
ROIC
10.6%Watch
Cash
$3MConcern
ANALYST COVERAGE3 analysts
BUY
+71.0%upside to target
Buy
3100%
3 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
RSI RangeRSI 32 — Bearish momentum
Volume
Volume FlowDistribution — institutional selling
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 2.14 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentSep 9, 2026
In 116 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendGolden Cross · 50D leads 200D by 3.5%

-8.8% vs SMA 50 · -5.6% vs SMA 200

Momentum

RSI32.1
Momentum fading
MACD-0.40
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$11.04+25.9%
EMA 50
$9.37+6.8%
EMA 200
$8.86+1.0%
Current
$8.77
52W Low
$5.08-42.1%
52-Week RangeMid-range
$5.0862th %ile$11.04
Squeeze SetupVolume-based
Distribution Pressure

Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.

20-Day Money Flow
Acc days:5
Dist days:4
Edge:+1 acc
Volume Context
Avg Vol (50D)142K
Recent Vol (5D)
335K+136%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 3 analysts
Analyst revisions:EPS↑ Revised UpRevenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2023
$129.4M
$128.4M$130.8M
$0.02
±1%
Low1
FY2024
$135.9M
$134.9M$137.5M
+5.1%$0.14+725.6%
±1%
Low2
FY2025
$143.9M
$143.8M$144.0M
+5.8%$0.29+103.5%
±2%
Moderate3
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 5 consecutive quarters
Earnings HistoryINFU
Last 8Q
+54.6%avg beat
Beat 6 of 8 quartersMissed 2 Estimates rising
-18%
Q3'24
+33%
Q4'24
-50%
Q1'25
+67%
Q2'25
+300%
Q3'25
+38%
Q4'25
+43%
Q1'26
+25%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
5 Buys/1 SellNet Buying
NET BUYERS$131K bought · $0 sold · 30d window
Gendron Paul AndrewDir
$44K
May 8
BUY
Lachance CarrieDir
$8K
May 11
BUY
Lachance CarrieDir
$18K
May 8
BUY
Steele Barry GExecutive VP a…
$61K
May 8
BUY
Steele Barry GExecutive VP a…
$19K
Mar 2
BUY
Shuda ScottDir
$56K
Aug 22
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
Minerva Advisors LLC
1.2M
2
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
838K
3
First Eagle Investment Management, LLC
721K
4
ACADIAN ASSET MANAGEMENT LLC
634K
5
BlackRock, Inc.
617K
6
DIMENSIONAL FUND ADVISORS LP
594K
7
RENAISSANCE TECHNOLOGIES LLC
567K
8
HEARTLAND ADVISORS INC
510K
News & Activity

INFU News

About

InfuSystem Holdings, Inc., is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services ('ITS'), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, and Wound Therapy businesses. The second platform, Durable Medical Equipment Services ('DME Services'), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payor clients. The DME Services segment is comprised of direct payor rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada.

Industry
Dental Laboratories
Addam ChupaExecutive Vice President & Chief Information Officer
Barry G. SteeleExecutive Vice President & Chief Financial Officer
Jerod FunkeExecutive Vice President & Chief HR Officer
Peers(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
INFU
$8.77+0.00%$177M22.4+635.8%462.0%1500
$404.35-3.20%$2.1T30.5+3296.8%4510.0%1500
$132.58-6.05%$307.9B20.7-44.8%1012.0%1500
$88.38-2.58%$303.7B13.6+318.8%1510.7%1500
$148.08-1.13%$282.6B21.0+597.3%2564.4%1500
$181.58-1.83%$281.6B26.9+862.9%1745.9%1500
$183.40-0.23%$256.1B16.8+213.3%1482.4%1500
Sector avg-2.15%21.7+840.0%1898.2%1500